Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

TSXV:BTI - Post Discussion

Bioasis Technologies Inc. > Everyone needs to relax!
View:
Post by zwerp2000 on Dec 14, 2022 5:35pm

Everyone needs to relax!

I know those that are still here are angry but did you expect? The ceo is a lightweight and never followed through with any of her promises and plans. The stock was near a 52 week low. The pipeline never materialized and moved forward. Prothena did nothing with the technology. Chiesi did nothing with the technology. I think it is just time to wake up and finally realize that the BBB platform technology was worthless. Sorry, but it is. No one had any interest, in all of these years, to push it forward. Yeah, the company at times hinted there was a huge demand but that was just fluff and smoke and mirrors. The truth is, the technology had no real utility.

Now I know some are angry about this deal which seemingly is horrible for shareholders. However, what did you expect? When you have a company with a failed platform and no money that is about to die, what kind of fantastic deal did you think was out there to be signed?? There wasn't any so this deal, which admittedly sucks for shareholders, was probably the only one available that could keep this company alive
Comment by JDavenport on Dec 14, 2022 5:47pm
Did xB3 fail, zwerp2000? Is that the program failure?  I think this deal is all about extracting xB3 from shareholder hands. If xB3 works as hoped then this deal is not caused by xB3 failure. Shareholders had every reason to expect success.  This deal is the result of 14 years of management failure. How can Ladenburg Thalmann and the Midatech people have any respect for DrDR when they ...more  
Comment by zwerp2000 on Dec 14, 2022 6:18pm
Did xB3 fail, zwerp2000? Is that the program failure? The answer is pretty obvious. XB3 failed. This is why the company has been scambling around to keep solvent and why they eventually had to sell out for peanuts. Prothena looked at the platform and for years, did nothing with it. Chiesi came in and did nothing with it either. If there was any utility to XB3 someone would have come in and moved ...more  
Comment by lovingold on Dec 15, 2022 1:53am
Did xB3 fail, zwerp2000? Is that the program failure? The answer is pretty obvious. XB3 failed. Absolutely, unequivocally, not a truthful statement. It's actually humourus what a blatant lie it is. Ask them in a public forum such as the webinar on Tuesday, or any Board member like Mario Saltarelli or Mei Mei (head scientist) if xB3 has failed in any study that Bioasis or any of ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities